Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting - Sironax

WALTHAM, Mass., April 22, 2026 — Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases, today announced the selection of an abstract for presentation in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting will take place from May 29 to June 2 in Chicago, IL.

Presentation details are below:

Poster Title: SARM1 Inhibition to Prevent Chemotherapy-Induced Peripheral Neuropathy: Translational and Early Clinical Evaluation of SIR2501

Poster Board: 131

Abstract #: 12148

Date/Time: May 30, 2026, 1:30-4:30 PM CDT

About Sironax

Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic and rare diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with NAMPT activator SIR4156, SARM1 inhibitor SIR2501, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups.